MB12-C-01-22, NCT05668650: Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC |
|
|
| Recruiting | 3 | 174 | RoW | Pembrolizumab, Keytruda, Pembrolizumab biosimilar, MB12 | Laboratorio Elea Phoenix S.A., Syneos Health | Non Small Cell Lung Cancer Metastatic | 08/25 | 12/25 | | |
